NanoVation Therapeutics, a Vancouver, BC, Canada-based platform company developing technologies to overcome barriers to nucleic acid delivery, raised an undisclosed amount in funding.
The round was led by Convergent Ventures.
The company intends to use the funds to support the further advancement of its lipid nanoparticle (LNP) technology platform for RNA delivery to cells outside of the liver, including the completion of large animal studies.
Led by Dominik Witzigmann, Ph.D., CEO, NanoVation Therapeutics specializes in the design and creation of lipid nanoparticles (LNPs) for nucleic acid delivery. Its LNP technologies aim to overcome the limits of existing approaches to nucleic acid delivery, including the ability to target tissues outside the liver (extrahepatic delivery). NanoVation’s lead technology is its proprietary long-circulating LNP (lcLNP™) platform, which enables functional nucleic acid delivery to extrahepatic cell types and has demonstrated an improved therapeutic index in preclinical studies.
The company partners with pharmaceutical and biotech companies to enable the development of genetic medicines for previously untreatable diseases.
The Board of Directors appointments included Zachariah (Zach) Jonasson, Ph.D., Chief Financial Officer (CFO) and Chief Business Officer (CBO) at Absci and co-founder of Convergent Ventures, and David Main, President and CEO of Notch Therapeutics.
FinSMEs
20/11/2024